Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Applies Emergency Measure To Purchase U.S. Bioaccess’s Bone Marrow Collection Sets

This article was originally published in PharmAsia News

Executive Summary

Japan Society for Hematopoietic Cell Transplantation ordered Dec. 5 150 bone marrow collection sets from Baltimore, Md. based company Bioaccess. After U.S. drug and device maker Baxter discontinued making the product last fall, the society has seen a decrease in inventory to 493 sets. With 150 bone marrow transplants taking place per month in Japan, the society placed the order with Bioaccess to assure the continuation of the treatments. Approved by U.S. FDA, Bioaccess's product has not been approved by Japan's Ministry of Health, Labor and Welfare. To avoid a potential discontinuation in bone marrow transplant surgeries, the MHLW has treated the purchase as an emergency measure and also allowed medical reimbursement for the product. (Click here for more - Japanese language

You may also be interested in...



Vous Has Advisors To Guide Growth In Promising Personalized Vitamin Space

Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.

Targeting Exciting Inflammasome Field, NodThera Raises $55m

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

Mylan And Pfizer Announce Key Date For Viatris Merger

Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel